Simvastatin for patients with acute respiratory distress syndrome: long-term outcomes and cost-effectiveness from a randomised controlled trial

Table 3 Mean (SD) EQ-5D-3L utilities and QALYs, by treatment group

	Simvastatin n = 139	Placebo n = 153	Difference (95% CI) simvastatin – placebo
	Mean (SD)	Mean (SD)	Difference (95% CI) simvastatin – placebo
6 months utility	0.316 (0.373)	0.222 (0.348)	0.094 (0.012 to 0.175)
12 months utility	0.315 (0.375)	0.244 (0.371)	0.070 (–0.014 to 0.155)
QALYs^a	0.136 (0.274)	0.072 (0.262)	0.064 (0.002 to 0.127)

^a Calculated using baseline (–0.402, 6-, and 12-month utilities)
CI confidence interval, EQ-5D-3L EuroQol Five Dimension (Three Level), QALY quality-adjusted life year, SD standard deviation

ISSN: 1364-8535